Cellectar Biosciences, Inc. (NASDAQ:CLRB) Q4 2023 Earnings Call Transcript

Jim Caruso : Yeah. So from a regulatory perspective, I’ll say that based off the clinical data that we’ve seen to date, as Andrei took you through, the one, yeah, we’re later line, but more importantly, the refractoriness of these patients, the level of treatments that they have received, we do believe that this — we have a very strong position and a strong opportunity to pursue a simplistic sort of second line or later positioning for as one might say a relapse/refractory patient population. So really targeting in on that sort of 11,000-ish patient population. We do believe that we have a very high probability of success on that, again, because of the number of patients that we’ve had that have been exposed not just the only approved class of therapy, but essentially all of their therapeutic options and for which they’ve shown high levels of refractoriness, unlike what’s been tested historically. And so we do believe that there’s a strong opportunity there.

Jeff Jones : Great. Really appreciate the additional clarity, guys. I’ll step back in to the queue.

Jim Caruso : All right. Thanks so much, Jeff.

Operator: Thank you. And currently, there are no further questions in the queue at this time. So I’ll hand the floor back to Mr. Caruso for the closing remarks.

Jim Caruso : All right. Terrific. Thank you, Mark. Appreciate your facilitation of this call today. And obviously, I would like to thank everyone for joining us as well. And we look forward to speaking with you in the near term. Have a good day.

Operator: This now concludes our call. Thank you all very much for attending. You may now disconnect.